Medical Department I, University Hospital Marien Hospital Herne, Ruhr University Bochum, Hölkeskampring 40, 44625, Herne, Germany.
Department of Cardiology and Angiology, Medical University Brandenburg, Brandenburg, Germany.
J Nephrol. 2019 Apr;32(2):315-321. doi: 10.1007/s40620-018-0554-7. Epub 2018 Nov 15.
Attempts to discontinue calcineurin inhibitors (CNIs) early after renal transplantation without conversion to an alternative immunosuppressive have failed due to high rates of acute rejection. Data on "late" CNI withdrawal are lacking so far.
We carried out a matched case-control study on the effects of CNI withdrawal on graft loss and mortality in 90 patients (1500 screened) with advanced graft dysfunction (serum creatinine > 3.5 mg/dl) and a cyclosporine-based triple immunosuppressive regimen at the Charité University Hospital, Berlin.
Cyclosporine was withdrawn at a mean of 54.0 ± 32.8 months post-transplant in 45 subjects. Whereas estimated glomerular filtration rate (eGFR) did not significantly differ between the groups at this time (12.4 ± 2.7 vs. 14.7 ± 8.9 in the control group, p = 0.08), it was significantly higher in subjects undergoing withdrawal after 120 months (Δ 4.1 ml/min; p < 0.001). In a Cox regression analysis adjusted for age, gender and eGFR, patients with CNI withdrawal showed better survival rates for the combined endpoint death/graft loss (hazard ratio, HR [95% confidence interval]: 0.19 [0.12-0.33], p = 0.001) compared to matched controls. The survival benefit was significant for the endpoints death (p = 0.01) and graft loss (p = 0.001).
CNI withdrawal was associated with improved survival rates in patients with advanced graft dysfunction in this retrospective analysis.
在肾移植后早期尝试停用钙调磷酸酶抑制剂(CNI)而不转换为替代免疫抑制剂,由于急性排斥反应的高发生率而失败。目前缺乏关于“晚期”CNI 停药的数据。
我们在柏林夏洛蒂大学医院进行了一项匹配病例对照研究,纳入了 90 例(筛选出 1500 例)移植后晚期肾功能障碍(血清肌酐>3.5mg/dl)和基于环孢素的三联免疫抑制方案的患者,评估 CNI 停药对移植物丢失和死亡率的影响。
45 例患者在移植后平均 54.0±32.8 个月时停用环孢素。此时两组的估计肾小球滤过率(eGFR)无显著差异(治疗组为 12.4±2.7,对照组为 14.7±8.9,p=0.08),但在 120 个月后停药的患者中 eGFR 显著升高(Δ4.1ml/min;p<0.001)。在调整年龄、性别和 eGFR 的 Cox 回归分析中,与匹配对照组相比,接受 CNI 停药的患者在死亡/移植物丢失的联合终点上显示出更好的生存率(风险比[95%置信区间]:0.19[0.12-0.33],p=0.001)。CNI 停药与死亡(p=0.01)和移植物丢失(p=0.001)终点的生存获益显著相关。
在这项回顾性分析中,CNI 停药与晚期移植物功能障碍患者的生存率提高相关。